# A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct06064877/  
OnCo record `nct06064877` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Ficlatuzumab in head and neck squamous cell carcinoma, now recruiting.

## Summary

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT06064877, led by AVEO Pharmaceuticals, and recruiting on the registry. Official title: A Multicenter, Randomised, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN). Planned enrolment is 410 participants (estimated). The study started in 2024-01-11 and primary completion is expected in 2027-08. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: FIERCE-HN
- Tags: ctgov-ingest
- Registry id: NCT06064877
- Phase: 3
- Setting: A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)
- Sponsor: AVEO Pharmaceuticals
- Enrolled: 410

## Sources

- ClinicalTrials.gov NCT06064877: https://clinicaltrials.gov/study/NCT06064877

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)](https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/), [Recurrent or metastatic head and neck squamous cell carcinoma](https://onco.cc/cancers/recurrent-metastatic-hnscc/)
- drugs: [Ficlatuzumab](https://onco.cc/drugs/ficlatuzumab/)
- companies: [AVEO Oncology (LG Chem)](https://onco.cc/companies/aveo/)

---
JSON: https://onco.cc/api/v1/entities/nct06064877.json